KYTX supply chain intelligence for Kyverna Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Kyverna Therapeutics, Inc. (KYTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ELEVATEBIO-BASECAMP-INC | ELEVATEBIO-BASECAMP-INC | 92% | Under the July 2023 development and manufacturing services agreement, or the Elevate Agreement, with ElevateBio BaseCamp, Inc., or Elevate, Elevate provides us with cell manufacturing, release and te… |
| MINARIS-ADVANCED-THERAPIES-INC | MINARIS-ADVANCED-THERAPIES-INC | 92% | Under the master services agreement with Minaris Advanced Therapies, Inc., or MAT, MAT’s facility in Philadelphia, Pennsylvania, provides us with certain customized cell manufacturing, release and te… |
| OXFORD-BIOMEDICA-UK-LIMITED | OXFORD-BIOMEDICA-UK-LIMITED | 90% | Pursuant to our license and supply agreement with Oxford Biomedica (UK) Limited, or Oxford, Oxford provides us with lentiviral vector process development servi |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or … |
| CABA | Cabaletta Bio, Inc. | 72% | Reciprocal relationship from CABA graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out… |
| CABA | Cabaletta Bio, Inc. | 72% | a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t… |
| CLYM | Climb Bio, Inc. | 72% | Reciprocal relationship from CLYM graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CLYM g… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | . The Company recognized $ million and in impairment charges related to capitalized software as research and development expenses in the statement of operations and comprehensive loss for the years e… |
| JNJ | Johnson & Johnson | 72% | a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exc… |
| NTLA | Intellia Therapeutics, Inc. | 72% | certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $ million fo… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: . The Company had material revenue from Kyverna or ONK during the years ended December 31, 2025, 2024 or 2023. $ Other investments Restricted cash equivalents… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective representations, warranties and obligations t… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK m… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD g… |
| GILD | Gilead Sciences, Inc. | 72% | ase 1 data from both of these trials in the second half of 2025. In November 2024, we presented clinical data at ACR Convergence 2024 that demonstrated positive sustained efficacy and durability at >… |
| MS-PE | Morgan Stanley | 72% | Reciprocal relationship from MS-PE graph: Reciprocal relationship from KYTX graph: businesses, strategic alliances, joint ventures and collaborations, to expand our existing technologies and operatio… |
| MS-PK | Morgan Stanley | 72% | businesses, strategic alliances, joint ventures and collaborations, to expand our existing technologies and operations. Any potential acquisition or strategic partnership may entail numerous risks, i… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from NTLA g… |
| NTLA | Intellia Therapeutics, Inc. | 72% | certain regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $ million fo… |
| BAIT-THERAPEUTICS-INC | BAIT-THERAPEUTICS-INC | 62% | cel, or miv-cel, and also known as KYV-101, is advancing through late-stage clinical development. The Company is currently focused on advancing its neuroimmunology CAR T franchise, which includes eva… |
| CELL-DESIGN-LABS-INC | CELL-DESIGN-LABS-INC | 62% | regulatory-and clinical-related benchmarks are due to the NIH, with the minimum cumulative royalty due for a product reaching FDA approval or foreign-equivalent approval totaling $ 5.7 million for th… |
| CME | CME Group Inc. | 62% | Reciprocal relationship from CME graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CME graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from CME grap… |
| CME-GROUP-BENCHMARK-ADMINISTRATOR-LIMITED | CME-GROUP-BENCHMARK-ADMINISTRATOR-LIMITED | 62% | ly due to a one-time $0.6 million impairment charge related to a capitalized software recorded during the three months ended March 31, 2025 and lower allocated overhead expenses. General and Administ… |
| ELEVATEBIO-BASECAMP-INC | ELEVATEBIO-BASECAMP-INC | 62% | ed deficit of $464.6 million. Management has determined that our cash and cash equivalents and available-for-sale marketable securities of $236.4 million as of March 31, 2026 will be sufficient to fu… |
| JEF | Jefferies Financial Group Inc. | 62% | Reciprocal relationship from JEF graph: Reciprocal relationship from KYTX graph: ly due to a one-time $0.6 million impairment charge related to a capitalized software recorded during the three months… |
| JEFFERIES-LLC | JEFFERIES-LLC | 62% | ly due to a one-time $0.6 million impairment charge related to a capitalized software recorded during the three months ended March 31, 2025 and lower allocated overhead expenses. General and Administ… |
| KITE-THERAPEUTICS-INC | KITE-THERAPEUTICS-INC | 62% | ich consisted of $86.7 million in proceeds from maturities of available-for-sale marketable securities, offset by $81.1 million of purchases of available-for-sale marketable securities. 30 Financing … |
| MINARIS-ADVANCED-THERAPIES-INC | MINARIS-ADVANCED-THERAPIES-INC | 62% | ed deficit of $464.6 million. Management has determined that our cash and cash equivalents and available-for-sale marketable securities of $236.4 million as of March 31, 2026 will be sufficient to fu… |
| OXFORD-FINANCE-LLC | OXFORD-FINANCE-LLC | 62% | care; • the reluctance of patients to switch from their existing therapy regardless of the safety and efficacy and/or logistical ease of newer products; • our ability to offer such product candidates… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| KYTX-DEBT | Debt stack $24.9M | 90% | Market cache reports total debt of $24.9M. |
| KYTX-DEBT-10598 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| KYTX-OWNER-GORDONMD-GLOBAL-INVESTMENTS-LP | GordonMD Global Investments LP | 90% | 13F overlay lists GordonMD Global Investments LP as top holder; 113 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CELU | Celularity Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 1 | ['supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| CRIS | Curis, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| ALMS | Alumis Inc. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| CME | CME Group Inc. | 100.00 | 1 | ['customer'] |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 1 | ['supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CGEM | Cullinan Therapeutics, Inc. | 100.00 | 2 | |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 2 |